Chest, Vol 102, 1384-1391, Copyright © 1992 by American College of Chest Physicians

ARTICLES

Two-year bronchodilator treatment in patients with mild airflow obstruction. Contradictory effects on lung function and quality of life

CP van Schayck, MP Rutten-van Molken, EK van Doorslaer, H Folgering and C van Weel
Department of Family Medicine and Pulmonary Diseases, Nijmegen University, The Netherlands.

In a two-year randomized controlled study, we studied the effects of bronchodilator treatment on the lung function and the quality of life in patients with mild airflow obstruction. The patients were randomly divided to receive either continuous or symptomatic bronchodilator treatment. Within these treatment groups, they received salbutamol in the first year and ipratropium bromide in the second or vice versa. In addition, the quality of life of the patients was compared to that of the general population. One hundred and forty-four patients completed the study. When compared to the general population, these patients showed a serious impairment in quality of life. No differences between the two drugs were found, but the results indicated that FEV1 decline in the continuously treated group was significantly larger than in the symptomatically treated group. However, this was not reflected in a significant deterioration of the quality of life in the continuous group as measured by means of the Nottingham Health Profile and the Inventory of Subjective Health. Decline in FEV1 showed no correlation with changes in quality of life scores. This may be due to a relatively rapid adjustment of the patients to a decline in FEV1, as a result of which it has no direct effect on the experienced quality of life. Another reason may be that continuous bronchodilation masks the worsening of the disease. This lack of awareness might in turn be caused by the continuous symptom relief of bronchodilators.

This article has been cited by other articles:

				J.R. Curtis and D.L. Patrick The assessment of health status among patients with COPD Eur. Respir. J., June 1, 2003; 21(41_suppl): 36S - 45s. [Abstract] [Full Text] [PDF]

				W. R. Douma, H. A. M. Kerstjens, A. de Gooijer, S. E. Overbeek, G. H. Koeter, and D. S. Postma Initial Improvements in Lung Function and Bronchial Hyperresponsiveness Are Maintained During 5 Years of Treatment With Inhaled Beclomethasone Dipropionate and Terbutaline Chest, January 1, 2002; 121(1): 151 - 157. [Abstract] [Full Text] [PDF]

				J. Jacobs, E. van de Lisdonk, I Smeele, C van Weel, and R. Grol Management of patients with asthma and COPD: monitoring quality of life and the relationship to subsequent GP interventions Fam. Pract., December 1, 2001; 18(6): 574 - 580. [Abstract] [Full Text] [PDF]

				D. A. Mahler How Should Health-Related Quality of Life Be Assessed in Patients With COPD? Chest, February 1, 2000; 117(2_suppl): 54S - 57S. [Abstract] [Full Text] [PDF]

				J. W. Ramsdell, N. M. Klinger, B. P. Ekholm, and G. L. Colice Safety of Long-term Treatment With HFA Albuterol Chest, April 1, 1999; 115(4): 945 - 951. [Abstract] [Full Text] [PDF]

				J. R. CURTIS, D. P. MARTIN, and T. R. MARTIN Patient-assessed Health Outcomes in Chronic Lung Disease . What are They, How Do They Help Us, and Where Do We Go From Here? Am. J. Respir. Crit. Care Med., October 1, 1997; 156(4): 1032 - 1039. [Full Text] [PDF]